Communiqués Alembic Limited

Actions

ALEMBICLTD

INE426A01027

Marché Fermé - Bombay S.E. Autres places de cotation 12:00:57 05/07/2024			Varia. 5j.	Varia. 1 janv.
120,3 ^INR	+3,98 %		+8,23 %	+32,77 %

30/05	Alembic Pharmaceuticals reçoit le feu vert final de la FDA pour ses comprimés de Sacubitril et de Valsartan	MT
13/05	Alembic Limited recommande le versement d'un dividende pour l'exercice clos le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Alembic Pharmaceuticals - Revenue up 18% to Rs. 1486 crores in Q-1 FY24	07/08/23	AQ
Alembic : Annual Report 2022-23	12/07/23	PU
Alembic : AL-Extract-Consolidated Financial Result-IE-Eng-12.05.2023	12/05/23	PU
Alembic : AL-Extract-Consolidated Financial Result-FE-Guj-12.05.2023	12/05/23	PU
Alembic : Audited Financial Results for the Quarter and Financial year ended 31st March, 2023	12/05/23	PU
Alembic Pharmaceuticals receives USFDA Final Approval for Cyclophosphamide Capsules 25 mg and 50 mg	14/11/22	AQ
Alembic Pharmaceuticals announces its first injectable product approval from its General Sterile Facility Final Approval for Glycopyrrolate Injection USP	02/11/22	AQ
Alembic Pharmaceuticals receives USFDA Final Approval for Paclitaxel Injection USP, 30 mg/5 mL, 100 mg/16.7 mL, and 300 mg/50 mL Multiple-Dose Vials.	28/10/22	AQ
Alembic : Spurt in Volume	04/10/22	PU
TTAB Trifusal: ALEMBIC PHARMACEUTICALS Refusals Affirmed - Likelihood Of Confusion, Failure-to-Function, And Nonuse	16/09/22	AQ
Alembic Pharmaceuticals receives USFDA Final Approval for Chlorthalidone Tablets USP, 25 mg and 50 mg.	30/08/22	AQ
Alembic Pharmaceuticals announces its wholly owned subsidiary, Aleor Dermaceuticals Limited receives USFDA Final Approval for Adapalene and Benzoyl Peroxide Topical Gel, 0.3%/2.5%	09/08/22	AQ
Alembic reports revenue for Q1 FY23 Rs. 1262 Cr.	05/08/22	AQ
Alembic Pharmaceuticals announces its wholly owned subsidiary, Aleor Dermaceuticals Limited receives USFDA Final Approval for Diclofenac Sodium Topical Gel, 3%	01/08/22	AQ
Alembic Pharmaceuticals receives USFDA Final Approval for Pirfenidone Tablets, 267 mg a~d 801 mg	25/05/22	AQ
Alembic Pharmaceuticals announces USFDA Tentative Approval for Dabigatran Etexilate Capsules, 75 mg, 110 mg, and 150 mg	08/04/22	AQ
Alembic : Pharmaceuticals announces its joint venture Aleor Dermaceuticals receives USFDA Final Approval for Metronidazole Gel USP. 1%	07/09/21	AQ
Alembic : Pharmaceuticals announces USFOA Final Approval for Erlotinib Tablets, 25 mg, 100 mg, and 150 mg.	12/07/21	AQ
Alembic : Pharmaceuticals announces USFDA Final Approval for Desipramine Hydrochloride Tablets USP, 10 mg. 25 mg. 50 mg, 75 mg, 100 mg, and 150 mg	09/07/21	AQ
Alembic : Pharmaceuticals announces its joint venture Aleor Dermaceuticals receives USFDA Tentative Approval for Metronidazole Gel USP, 1%.	05/05/21	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Alembic Limited

Actions

ALEMBICLTD

INE426A01027

Communiqués

Filtres